WeVote
Log In

Bill

Bill

HR 1620

Finn Sawyer Access to Cancer Testing Act

119th Congress Introduced by Don Bacon and 13 co-sponsors

The Finn Sawyer Access to Cancer Testing Act ensures equitable access to cancer testing, improving early detection and treatment for all, especially underserved communities.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 1620

Summary of HR 1620 - Finn Sawyer Access to Cancer Testing Act

Overview

The Finn Sawyer Access to Cancer Testing Act (HR 1620) is a legislative proposal introduced in the House of Representatives on February 26, 2025. The bill aims to enhance access to cancer testing services for individuals across the United States, addressing disparities in healthcare access and improving early detection of cancer.

Purpose and Intent

The primary purpose of HR 1620 is to ensure that all individuals, regardless of their socioeconomic status or geographic location, have equitable access to essential cancer testing services. The bill seeks to reduce barriers that prevent timely diagnosis and treatment of cancer, ultimately aiming to improve health outcomes and survival rates.

Key Provisions

While the specific provisions of HR 1620 are not detailed in the provided information, typical elements in similar legislation may include:

  • Increased Funding: Allocation of federal funds to support cancer testing programs, particularly in underserved communities.
  • Insurance Coverage Mandates: Requirements for private and public health insurance plans to cover a broader range of cancer screening tests without cost-sharing.
  • Outreach Programs: Initiatives to educate the public about the importance of cancer testing and available resources.
  • Partnerships with Healthcare Providers: Collaboration with local health departments and community organizations to facilitate access to testing.

Affected Parties

The bill is expected to impact several groups, including:

  • Patients: Individuals at risk for cancer who may face barriers to accessing testing services.
  • Healthcare Providers: Hospitals, clinics, and laboratories that provide cancer testing services.
  • Insurance Companies: Entities that will need to adjust their coverage policies to comply with the new mandates.
  • Public Health Organizations: Groups involved in cancer awareness and prevention efforts.

Legislative Process

As of its introduction, HR 1620 has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for further consideration. The Speaker of the House will determine the timeline for these committees to review the bill and make recommendations.

Related Legislation

HR 1620 has a companion bill, S 755, which is likely to be introduced in the Senate. The existence of a companion bill suggests a bipartisan interest in addressing the issues related to cancer testing access.

Conclusion

The Finn Sawyer Access to Cancer Testing Act represents a significant effort to improve access to cancer testing services in the United States. By addressing barriers to testing, the bill aims to enhance early detection and treatment of cancer, ultimately contributing to better health outcomes for individuals at risk. Further developments in the legislative process will clarify the specific provisions and funding mechanisms proposed in this bill.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.